Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM.

Br J Clin Pharmacol. 1998 Dec;46(6):563-70.

2.
3.

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.

Foster GR.

Expert Opin Pharmacother. 2003 May;4(5):685-91. Review.

PMID:
12739994
4.

Peginterferon-alpha(2b) and ribavirin.

Ahn J, Flamm S.

Expert Rev Anti Infect Ther. 2004 Feb;2(1):17-25. Review.

PMID:
15482168
5.

Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.

Rustgi VK.

Curr Med Res Opin. 2009 Apr;25(4):991-1002. doi: 10.1185/03007990902779186 . Review.

PMID:
19275518
6.
7.

Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients.

Patel K, McHutchison J.

Expert Opin Pharmacother. 2001 Aug;2(8):1307-15. Review.

PMID:
11584999
8.

[Novel mode of action of ribavirin (Rebetol), a drug for the treatment of chronic hepatitis C: inducting the mutation of RNA viruses].

Ogawa M, Morisada A.

Nihon Yakurigaku Zasshi. 2002 Dec;120(6):398-408. Review. Japanese.

PMID:
12528471
9.

The clinical pharmacology of ribavirin.

Glue P.

Semin Liver Dis. 1999;19 Suppl 1:17-24. Review.

PMID:
10349689
10.

Safety of interferon beta treatment for chronic HCV hepatitis.

Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A, Colecchia A.

World J Gastroenterol. 2004 Jan;10(1):12-6. Review.

11.

Combination treatment for chronic hepatitis C: what is the role of ribavirin?

Souvignet C, Zarski JP.

Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):321-5. Review.

PMID:
11030438
12.

[The interferons: pharmacology, mechanism of action, tolerance and side effects].

Arnaud P.

Rev Med Interne. 2002 Nov;23 Suppl 4:449s-458s. Review. French.

PMID:
12481400
13.

Sylatron: a pegylated interferon for use in melanoma.

Patel JN, Walko CM.

Ann Pharmacother. 2012 Jun;46(6):830-8. doi: 10.1345/aph.1Q791. Epub 2012 May 22. Review.

PMID:
22619474
14.

Thymosin alpha-1.

Ancell CD, Phipps J, Young L.

Am J Health Syst Pharm. 2001 May 15;58(10):879-85; quiz 886-8. Review.

PMID:
11381492
15.

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P.

Cancer. 2002 Jul 15;95(2):389-96. Review.

16.

[Pegylated interferons: pharmacological basis].

Macquin-Mavier I, Hezode C, Dhumeaux D.

Gastroenterol Clin Biol. 2002 Aug-Sep;26(8-9):742-7. Review. French. No abstract available.

17.

Interferon-alpha in malignant and viral diseases. A review.

Dorr RT.

Drugs. 1993 Feb;45(2):177-211. Review.

PMID:
7681371
18.

Mechanisms of action of ribavirin in antiviral therapies.

Tam RC, Lau JY, Hong Z.

Antivir Chem Chemother. 2001 Sep;12(5):261-72. Review.

PMID:
11900345
19.

Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.

Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG.

Nat Biotechnol. 2007 Dec;25(12):1411-9. Review.

PMID:
18066038
20.

Clinical pharmacokinetics of interferons.

Wills RJ.

Clin Pharmacokinet. 1990 Nov;19(5):390-9. Review.

PMID:
1702693

Supplemental Content

Support Center